{"id":469511,"date":"2025-05-20T00:00:00","date_gmt":"2025-05-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0004-biopharma-wet-age-related-macular-degeneration-epidemiology-epidemiology-wet-age-related-macular-3\/"},"modified":"2026-03-31T10:26:11","modified_gmt":"2026-03-31T10:26:11","slug":"epidop0004-biopharma-wet-age-related-macular-degeneration-epidemiology-epidemiology-wet-age-related-macular-3","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0004-biopharma-wet-age-related-macular-degeneration-epidemiology-epidemiology-wet-age-related-macular-3\/","title":{"rendered":"Wet Age-related Macular Degeneration &#8211; Epidemiology &#8211; Epidemiology &#8211; Wet Age-Related Macular Degeneration &#8211; Europe"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of wet age-related macular degeneration (<abbr title=\"age-related macular degeneration\">AMD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> forecast will answer the following questions:<\/p>\n<ul>\n<li>Of all people diagnosed with wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr>, how many in each country in the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 6 wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> patient populations, as follows:<\/p>\n<ul>\n<li>Total prevalent cases of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Total prevalent cases of mixed <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed prevalent cases of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Undiagnosed prevalent cases of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed drug-treated prevalent cases of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed non-drug-treated prevalent cases of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-469511","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-geography-europe","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469511\/revisions"}],"predecessor-version":[{"id":469866,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469511\/revisions\/469866"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=469511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}